Oxygen Of The Saccharide Radical Bonded To A Nonsaccharide Hetero Ring By Acyclic Carbon Bonding Patents (Class 514/32)
  • Patent number: 10376529
    Abstract: The present invention is related to a product comprising a pentacyclic triterpene of formula (I) and a hydroxytyrosol or derivatives thereof of formula (II), pharmaceutical compositions thereof and their uses as antioxidants, anti-inflammatories and neuron protectors.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: August 13, 2019
    Assignee: NATAC BIOTECH, S.L.
    Inventors: José Carlos Quintela Fernández, Esther De La Fuente García, Marco Pugliese, Pilar Mancera Aroca, Javier Bustos Santafé, Juan Francisco Espinosa Parrilla, Noemí Virgili Treserres, Blanca Wappenhans Battestini
  • Patent number: 10342802
    Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: July 9, 2019
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd Henderson, David Griffin
  • Patent number: 10105380
    Abstract: A molecule responding to formula (I) of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by Pseudomonas aeruginosa, more specifically as inhibitors of Pseudomonas aeruginosa's virulence.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: October 23, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER 1
    Inventors: Francois Morvan, Jean-Jacques Vasseur, Caroline Ligeour, Yann Chevolot, Eliane Souteyrand, Olivier Vidal, Alice Goudot, Sebastien Vidal
  • Patent number: 9919000
    Abstract: Proton mopping is a new anti-cancer therapeutic approach that disrupts cancer's immunologic balance. It results in the alteration of the pHi/pHe ratio (intracellular-extracellular) of the cancer cell, leading cancer to either normalcy or apoptosis. This technology deploys a chemical compound that has two parts, a glucose part to guide the molecule to the cancer site and a proton neutralizer to mop up the protons. Proof of the validity of this therapeutic approach came after using an existing chemical compound 2-[2(2-Aminoethoxy)ethoxy]ethyl a-D-mannopyranoside, C12H25NO8, which has the above mentioned properties. This compound is of the class of functionalized PEGylated glycosides, which are ligands for conjugation to biological molecules.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: March 20, 2018
    Inventor: Michael Theodore Lytinas
  • Patent number: 9868715
    Abstract: Certain embodiments are directed to apigenin analogues or derivatives. In certain aspects, the derivatives are developed as cystathionine-beta-synthase (CBS) inhibitors. In certain aspects, the derivatives are used as anticancer or anti-inflammatory agents. Certain embodiments are directed methods of treating or compositions used to treat fibrosis and cancers. In certain aspects one or more compounds described herein can be administered to a subject to treat pancreatic fibrosis, liver fibrosis, pancreatic cancer, colon cancer, breast cancer, brain tumors, head/neck cancer, prostate and lung cancers as well as other inflammation.
    Type: Grant
    Filed: April 18, 2015
    Date of Patent: January 16, 2018
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS
    Inventors: Jia Zhou, Mark Hellmich, Csaba Szabo
  • Patent number: 9446006
    Abstract: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract.can be used to maintain or increase mitochondrial biogenesis in cardiac muscle, skeletal muscles, and liver tissue.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: September 20, 2016
    Assignee: DSM IP ASSETS B.V.
    Inventors: Ann Fowler, Angelika Friedel, Darko Knutti, Karin Kuratli, Daniel Raederstorff, Ying Wang-Schmidt, Karin Wertz
  • Patent number: 9284274
    Abstract: The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 15, 2016
    Assignee: RAMOT at Tel-Aviv University Ltd.
    Inventors: Yoel Kashman, Eliezer Flescher, Max Herzberg
  • Patent number: 9150568
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: October 6, 2015
    Assignee: NOVARTIS AG
    Inventors: David C. Tully, Paul Vincent Rucker, Phillip B. Alper, Daniel Mutnick, Donatella Chianelli
  • Patent number: 9006468
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: April 14, 2015
    Assignee: Dow AgroSciences, LLC.
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
  • Publication number: 20150065440
    Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 5, 2015
    Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond
  • Patent number: 8962576
    Abstract: Compositions of natural antioxidants, especially those derived from Phyllanthus emblica and Withania somnifera, and combinations thereof, are provided. The compositions may be used for improvement of endothelial function and cardiovascular health, including treatment of diabetes.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: February 24, 2015
    Assignee: Natreon, Inc.
    Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
  • Patent number: 8962575
    Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: February 24, 2015
    Assignee: Biotropics Malaysia Berhad
    Inventors: Matthias Gehling, Torsten Grothe, Ernst Roemer, Peter Reinemer, Kathrin Reinhardt, Annie George, Nur Hanisah Mohtar, Noorsyarida Mohd Sapiai
  • Publication number: 20150050356
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Vuong TRIEU
  • Publication number: 20150038406
    Abstract: The present invention relates to pharmaceutical formulations comprising tranexamic acid, kits thereof, and methods for treating bleeding by local administration.
    Type: Application
    Filed: July 8, 2014
    Publication date: February 5, 2015
    Inventors: Matthew James Buderer, Jeffrey Joel Abrams
  • Publication number: 20150025028
    Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 22, 2015
    Inventors: Guey-Jen LEE-CHEN, Hsiu-Mei HSIEH, Guan-Chiun LEE
  • Publication number: 20150018294
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides for methods and pharmaceutical agents to modulate the activity of Tousled-like kinase (TLK). The invention also provides for methods and pharmaceutical agents to inhibit the activity of Tousled-like kinase to provide increased sensitivity to irradiation (IR) and chemotherapeutic agents. The invention also provides for methods and pharmaceutical agents to increase the activity of Tousled-like kinase to provide increased protection against DNA damaging agents including to irradiation (IR) and chemotherapeutic agents.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 15, 2015
    Inventors: Arrigo DE BENEDETTI, Gulshan SUNAVALA
  • Publication number: 20140378402
    Abstract: Disclosed is a pharmaceutical composition containing as an active ingredient a compound represented by formula (I) or a physiologically acceptable salt thereof, and a method for treating cancer, the method including administering the compound represented by formula (I) or the physiologically acceptable salt thereof.
    Type: Application
    Filed: January 29, 2013
    Publication date: December 25, 2014
    Applicant: NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Shigenobu Yano, Takashi Shibahara, Shunichiro Ogura
  • Publication number: 20140364386
    Abstract: The present invention relates to methods of modifying nematode behavior using certain isolated modulator compounds. Also disclosed are methods of promoting or inhibiting reproduction in a nematode population, methods of promoting or inhibiting nematode aggregation at a first location, and methods of treating or preventing parasite infection of a plant.
    Type: Application
    Filed: August 8, 2012
    Publication date: December 11, 2014
    Applicants: California Institute of Technology, Boyce Thompson Institute for Plant Research
    Inventors: Andrea Choe, Paul W. Sternberg, Frank C. Schroeder, Stephan H. Von Reuss, Fatma Kaplan, Peter A. Teal, Hans Alborn
  • Publication number: 20140349955
    Abstract: Disclosed in the present invention is the use of a fluorine-containing in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (I). Experiments have demonstrated that the present fluorine-containing water soluble platinum complex is highly water soluble and exhibiting superior cytotoxicity and efficacy compare to the clinical platinum drugs. Said complex alone or in combination with other chemotherapeutics is able to treat cancer in mammals, and in particular, humans, said cancers including lung cancer, colon cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoid cancer, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, gastric cancer, male genital cancer or bone cancer.
    Type: Application
    Filed: June 22, 2012
    Publication date: November 27, 2014
    Applicant: GUDUI BIPHARMA TECHNOLOGY INC.
    Inventors: Yiqiang Wang, Yang Liu
  • Patent number: 8895518
    Abstract: The present invention relates to an intermolecular association complex of an amphiphilic carrier and an active principle G, having the following general formula (I), as well as to the compositions containing same, to the uses thereof, particularly as a drug, and to the method for preparing same.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: November 25, 2014
    Assignees: Centre National de la Recherche Scientifique, Universite Paul Sabatier Toulouse III
    Inventors: Cécile Bize, Muriel Blanzat, Emile Perez, Isabelle Rico-Lattes
  • Publication number: 20140315837
    Abstract: This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier.
    Type: Application
    Filed: July 3, 2014
    Publication date: October 23, 2014
    Inventors: Deborah C. Mash, Richard D. Gless
  • Publication number: 20140309182
    Abstract: The present invention relates to an insecticidal enriched extract (biopesticide) isolated from the stem of Nothapodites foetida (Wight) Sleumer (formerly Mappia foetida (Miers) useful for the insect free storage and transport of grains and seed. The insecticidal activity of the enriched extract (biopesticide) of the invention is ascribed to compound/s other than camptothecin. The invention further relates to the process for preparation thereof, containing Compounds of general formula 1 and formula 2 (General formula 1) wherein R1=CH3, CH2OAC and wherein R2=COOH, or (I) and R3=H. OH.
    Type: Application
    Filed: June 21, 2012
    Publication date: October 16, 2014
    Inventors: Swati Pramod Joshi, John Pereira, Phool Kumar Patanjali, Sunita Sharad Kunte, Kiran Babasaheb Sonawane, Suresh Gurappa Mummigatti, Sumithra Devi Sanna, Krishnaiah Eraiah Hullukere, Seema Chaudhary
  • Publication number: 20140296068
    Abstract: This document discloses molecules having the following formula (Formula One) and processes related thereto.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 2, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Negar Garizi, Tony K. Trullinger, Ricky Hunter, Yu Zhang, Noormohamed M. Niyaz, Daniel Knueppel, Christian T. Lowe, Ann M. Buysse
  • Patent number: 8841264
    Abstract: Compositions containing a combination of hydroxytyrosol and resveratrol or liqustilide or (?)-epigallocatechin gallate or honokiol or genistein or Magnolia bark extract or a combination of oleuropein and resveratrol or ligustilide are used to treat inflammatory disorders.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: September 23, 2014
    Assignee: DSM IP Assets B.V.
    Inventors: Daniel Raederstorff, Nathalie Richard, Joseph Schwager, Karin Wertz
  • Publication number: 20140249347
    Abstract: The present invention is directed to a novel use of pyridone derivatives such as pirfenidone for the prevention and treatment of damages to tissues or organs induced by various cytotoxic agents, such as chemotherapeutic agents, biologics, immunosuppressants and radiation. Such prophylactic and/or therapeutic effects of the pyridone derivatives make it possible to increase therapeutic dosages of the cytotoxic agent, thereby enhancing the therapeutic efficacy of the cytotoxic agent and radiation therapy.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicant: Shanghai Genomics, Inc.
    Inventor: Jun Wu
  • Publication number: 20140228310
    Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 14, 2014
    Applicant: InterMune, Inc.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid D. Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
  • Publication number: 20140187507
    Abstract: This invention provides compounds, compositions, and methods for treating Parkinson's disease. In particular, there is provided GM1 ganglioside analogs that are capable of penetrating the blood brain barrier and entering the cytoplasm of neurons. Endogenous GM1 interacts with the with GFR?1/RET, the GDNF receptor complex involved in GDNF signaling which is essential for neuron survival. In neurons that are deficient in endogenous GM1, the GM1 analog compounds of the invention are capable of restoring GDNF signaling thereby preventing neuron cell death.
    Type: Application
    Filed: December 16, 2013
    Publication date: July 3, 2014
    Inventors: Shawn DeFrees, Robert Ledeen, Gusheng Wu
  • Publication number: 20130331349
    Abstract: The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
    Type: Application
    Filed: November 30, 2011
    Publication date: December 12, 2013
    Inventors: David C. Tully, Paul Vincent Rucker, Phillip B. Alper, Daniel Mutnick, Donatella Chianelli
  • Patent number: 8592383
    Abstract: The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R1, R2, R7, R8, R8a, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xianhai Huang, Jason Brubaker, Scott L. Peterson, John W. Butcher, Joshua T. Close, Michelle Martinez, Rachel Nicola MacCoss, Joon O. Jung, Phieng Siliphaivanh, Hongjun Zhang, Robert G. Aslanian, Purakkattle Johny Biju, Li Dong, Ying Huang, Kevin D. McCormick, Anandan Palani, Ning Shao, Wei Zhou
  • Publication number: 20130310331
    Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.
    Type: Application
    Filed: October 7, 2010
    Publication date: November 21, 2013
    Applicant: ZADEC APS
    Inventors: Elizabeth Joubert, Stephen John Fey, Johan Louw, Trond Ulven, Rahul Tyagi
  • Patent number: 8569249
    Abstract: Provided is a method for inhibiting the activation of macrophages in a subject, comprising administrating to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable ester of the compound, and combinations thereof:
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: October 29, 2013
    Assignee: China Medical University
    Inventors: Wen-Chuan Lin, Jin-Bin Wu, Hui-Ya Ho, Hung-Bo Hsiao
  • Publication number: 20130281393
    Abstract: The present invention provides novel and advantageous materials and methods for preventing and treating viral infection.
    Type: Application
    Filed: April 16, 2013
    Publication date: October 24, 2013
    Applicants: VERSITECH LIMITED, PURAPHARM COMPANY LIMITED
    Inventors: ALLAN SIK YIN LAU, LAI HUNG CINDY YANG
  • Patent number: 8551914
    Abstract: Molecules having the following structure are disclosed. Processes of using such molecules are disclosed.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: October 8, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: Lawrence C. Creemer, Gary D. Crouse, Thomas C. Sparks, CaSandra Lee McLeod
  • Patent number: 8551963
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: October 8, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Julius L. Apuy, Darren E. Insko, Joyce J. James
  • Patent number: 8486901
    Abstract: Novel sodium channel blocking compounds tetrodotoxm galactopyranosides of formula I were isolated and purified by HPLC and identified further through IR, NMR, GC, and MS. The compounds have a galactopyranosyl moiety attached to C11 of tetrodotoxin and retain the analgesic activity of the latter. Pharmaceutical compositions and medical uses thereof are further disclosed.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: July 16, 2013
    Assignee: Wex Medical Limited
    Inventor: Weiyang Lin
  • Publication number: 20130178435
    Abstract: Provided are methods for prognosing a clinical outcome in a subject with a hematological disorder comprising determining a 3D telomeres organization signature of a test sample cell from the subject, wherein the 3D telomeres organization signature of the test sample cell is indicative of the clinical outcome of the subject.
    Type: Application
    Filed: December 3, 2012
    Publication date: July 11, 2013
    Inventors: Sabine Mai, Hans Knecht, Macoura Gadji, Ade Olujohungbe
  • Publication number: 20130079293
    Abstract: Isolated compounds from adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the adelostemma gracillimum refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention.
    Type: Application
    Filed: March 18, 2011
    Publication date: March 28, 2013
    Applicant: BIOTECHNOLOGY RESEARCH CORPORATION LIMITED
    Inventors: Nancy Yuk-yu Ip, Fanny Chui-Fun Ip, Shengjun Guo
  • Patent number: 8394774
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: March 12, 2013
    Assignee: Dow AgroSciences, LLC.
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, Annette V. Brown, Thomas L. Siddall
  • Patent number: 8394797
    Abstract: The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to pyrazole derivatives of formula I and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use therapy and prophylaxis, in particular for the treatment of psychosis or pain.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: March 12, 2013
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Jordi Corbera Arjona, Maria Rosa Cuberes-Altisent, Joerg Holenz, Daniel Martínez-Olmo, David Vaño-Domenech
  • Publication number: 20130017162
    Abstract: The invention relates to a cosmetic composition, especially a hair composition, and to a method for the cosmetic treatment of keratin materials, especially of the hair, employing compounds of formula: in which Z represents (i) a hydrogen atom, (ii) a linear or branched C1 to C32 (saturated) alkyl radical; (iii) a linear or branched C2 to C32 (unsaturated) alkene radical, comprising one or two C?C double bonds; (iv) an aryl-substituted alkyl radical; said radicals being optionally substituted and/or interrupted.
    Type: Application
    Filed: January 4, 2011
    Publication date: January 17, 2013
    Applicant: L'OREAL
    Inventors: Anne-Claude Dublanchet, Christian Blaise, Abel Messavussu
  • Publication number: 20120329743
    Abstract: The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R1, R2, R7, R8, R8a, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.
    Type: Application
    Filed: June 14, 2012
    Publication date: December 27, 2012
    Inventors: Xianhai Huang, Jason Brubaker, Scott L. Peterson, John W. Butcher, Joshua T. Close, Michelle Martinez, Rachel Nicola MacCoss, Joon O. Jung, Phieng Siliphaivanh, Hongjun Zhang, Robert G. Aslanian, Purakkattle Johny Biju, Li Dong, Ying Huang, Kevin D. McCormick, Anandan Palani, Ning Shao, Wei Zhou
  • Publication number: 20120258924
    Abstract: Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.
    Type: Application
    Filed: June 20, 2012
    Publication date: October 11, 2012
    Applicant: INTERMUNE, INC.
    Inventors: Lawrence M. Blatt, Scott D. Seiwert, Leonid Beigelman, Ramachandran Radhakrishnan, Karl Kossen, Vladimir Serebryany
  • Publication number: 20120245113
    Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.
    Type: Application
    Filed: February 22, 2012
    Publication date: September 27, 2012
    Applicant: BIOTROPICS MALAYSIA BHD
    Inventors: Matthias GEHLING, Torsten GROTHE, Ernst ROEMER, Peter REINEMER, Kathrin REINHARDT, Annie GEORGE, Nur Hanisah MOHTAR, Noorsyarida Mohd Sapiai
  • Patent number: 8273763
    Abstract: Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used to treat sarcoglycanopathies.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: September 25, 2012
    Assignees: Genethon, Centre National de la Recherche Scientifique
    Inventor: Isabelle Richard
  • Publication number: 20120214756
    Abstract: The present invention relates to an intermolecular association complex of an amphiphilic carrier and an active principle G, having the following general formula (I), as well as to the compositions containing same, to the uses thereof, particularly as a drug, and to the method for preparing same.
    Type: Application
    Filed: October 4, 2010
    Publication date: August 23, 2012
    Applicants: UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Cécile Bize, Muriel Blanzat, Emile Perez, Isabelle Rico-Lattes
  • Publication number: 20120128662
    Abstract: The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.
    Type: Application
    Filed: April 24, 2010
    Publication date: May 24, 2012
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marcus Koppitz, Benjamin Bader, Ulf Bömer, Bertolt Kreft, Philip Lienau, Tobias Marquardt, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
  • Patent number: 8178658
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: May 15, 2012
    Assignee: Dow AgroSciences, LLC
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
  • Publication number: 20120101054
    Abstract: Novel sodium channel blocking compounds tetrodotoxm galactopyranosides of formula I were isolated and purified by HPLC and identified further through IR, NMR, GC, and MS. The compounds have a galactopyranosyl moiety attached to C11 of tetrodotoxin and retain the analgesic activity of the latter. Pharmaceutical compositions and medical uses thereof are further disclosed.
    Type: Application
    Filed: March 26, 2010
    Publication date: April 26, 2012
    Applicant: Wex Medical Limited
    Inventor: Weiyang Lin
  • Publication number: 20120076851
    Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
    Type: Application
    Filed: May 24, 2011
    Publication date: March 29, 2012
    Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
  • Publication number: 20120070410
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Application
    Filed: November 5, 2009
    Publication date: March 22, 2012
    Inventors: Julius L. Apuy, Darren E. Insko, Joyce J. James